pegozafermin
Recombinant proteinexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Jul 29, 2019 (NCT04048135)
Timeline
Indications
Mechanism of action
- KlothoAGONIST
KL agonist
- Fibroblast growth factor 21Supplementation
FGF21 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594466 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06419374 | Phase 3 | May 24, 2024 | 89bio Ltd. |
| NCT06318169 | Phase 3 | Mar 13, 2024 | 89bio Ltd. |
| NCT05852431 | Phase 3 | Jun 15, 2023 | 89bio Ltd. |
| NCT05022693 | Phase 1 | Aug 16, 2021 | 89bio Ltd. |
| NCT04929483 | Phase 2 | Jun 4, 2021 | 89bio Ltd. |
| NCT04541186 | Phase 2 | Sep 1, 2020 | 89bio Ltd. |
| NCT04048135 | Phase 1/Phase 2 (Phase 2) | Jul 29, 2019 | 89bio Ltd., ProSciento, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 89bio Ltd. | For profit | 7 | 7 | 3 | 2019 |
| ProSciento, Inc. | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1